{{Rsnum
|rsid=6427528
|Gene=CD84
|Chromosome=1
|position=160546518
|Orientation=plus
|GMAF=0.1974
|Gene_s=CD84
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}[[rs6427528]] is a SNP in the chromosome 1q23 region apparently located near enough to the CD84 locus to affect it's expression.

A GWAS study of 2,700+ [[rheumatoid arthritis]] (RA) patients treated with one of three anti-TNF drugs found that [[rs6427528]](A) carriers had higher CD84 expression and responded better to [[etanercept]] treatment. The effect was statistically significant but not that large in magnitude, totaling 2.6% of the variance in response to etanercept treatment. The result was seen in European (Caucasian) patients, but perhaps due to small patient numbers, was not statistically supported in Japanese patients.{{PMID|23555300|OA=1
}}

{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 11.1 | 88.9
| HCB | 2.2 | 17.8 | 80.0
| JPT | 0.0 | 15.9 | 84.1
| YRI | 22.6 | 54.8 | 22.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 2.2 | 17.8 | 80.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23555300
  |Trait=Response to anti-TNF treatment in rheumatoid arthritis
  |Title=Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.
  |RiskAllele=A
  |Pval=2E-6
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}